The effect of parenteral selenium on outcomes of mechanically ventilated patients following sepsis: a prospective randomized clinical trial

Annals of Intensive Care

Table 4 The effect of VAP on clinical outcomes in study patients

Outcome (s)	Early VAP		OR [95 % CI]	P	Late VAP		OR [95 % CI]	P value
Outcome (s)	Yes	No	OR [95 % CI]	P	Yes	No	OR [95 % CI]	P value
DOMV, mean ± SD	10.6 ± 4	8.6 ± 5.5		0.17	13.3 ± 1.4	8.2 ± 4.8		<0.0001
Duration of ICU stay, mean ± SD	22.9 ± 15.5	20 ± 17.9		0.54	33 ± 17	16.5 ± 13.4		<0.0001
Duration of hospital stay, mean ± SD	25.5 ± 17	24 ± 23		0.78	37 ± 22	19.3 ± 15.6		0.002
Days on vasopressor therapy, mean ± SD	3.4 ± 4	5.5 ± 5		0.13	8.3 ± 5.3	2.4 ± 3		<0.0001
Incidence of new infection, n/N	8/33	8/21	0.6 [0.18–2]	0.60	13/19	3/35	46 [8–259]	<0.0001
Incidence of ARDS, n/N	3/33	4/21	0.57 [0.11–2.8]	0.47	4/19	3/35	3.9 [0.76–20]	0.087
Overall mortality, n/N	16/33	13/21	0.97 [0.33–2.8]	0.54	14/19	15/35	10 [1.8–47]	0.001

DOMV duration of mechanical ventilation, ICU intensive care unit, VAP ventilator-associated pneumonia, ARDS acute respiratory distress syndrome, SD standard deviation, OR odds ratio